PHELIX THERAPEUTICS LLC
Biotech · Defunct
Calpain inhibitor small molecules to prevent myofibroblast formation and treat organ fibrosis
- Grants
- $9.6M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Cathepsin L Inhibitors As Pan-coronavirus Therapeutics | $1,475,511 | |
| Federal grant | Department of Health and Human Services · Phase II · Cathepsin L Inhibitors As Pan Coronavirus Therapeutics | $4,382,085 | |
| Federal grant | Department of Health and Human Services · Phase I · Cathepsin B Inhibitors as Therapeutics for Ebola Infection | $222,382 | |
| Federal grant | Department of Health and Human Services · Phase I · Cathepsin B Inhibitors as Therapeutics for Ebola Infection | $222,382 | |
| Federal grant | Department of Health and Human Services · Phase II · Cathepsin L Inhibitors As Pan-coronavirus Therapeutics | $1,465,763 | |
| Federal grant | Department of Health and Human Services · Phase II · Cathepsin L Inhibitors As Pan-coronavirus Therapeutics | $1,440,811 | |
| Federal grant | Department of Health and Human Services · Phase I · Calpain Therapeutics to Inhibit Myofibroblast Generation in Fibrosis | $201,665 | |
| Federal grant | Department of Health and Human Services · Phase I · Calpain Therapeutics to Inhibit Myofibroblast Generation in Fibrosis | $201,665 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3294 | Inflamma Therapeutics, LLC | — | — |
| 3295 | CELLCHORUS INC. | — | — |
| 3296 | Viking Therapeutics, Inc. | — | $3.7M |
| 3297 | PHELIX THERAPEUTICS LLC | — | — |
| 3298 | Ferment Labs, Inc. | — | $900K |
| 3299 | Rhamnolipid, Inc. | — | $1.0M |
| 3300 | Starton Therapeutics Inc. | — | $11M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.